title: The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials.
abstract: Ranolazine has characteristic properties of a selective inhibitor of the inward sodium current. It is primarily indicated as an anti-anginal agent in patients with coronary artery disease and chronic stable angina. Recently, ranolazine has been noted to possibly impart beneficial effects in various other cardiac conditions, including new-onset, paroxysmal, and chronic atrial fibrillation, post-operative atrial fibrillation, ventricular arrhythmias, post-revascularization coronary artery disease, chemotherapeutic cardiotoxicity, and diastolic and microvascular dysfunction. Herein, we present a review of the current clinical evidence describing the adjunctive or synergistic effects of ranolazine in non-angina related cardiovascular disorders, and include a discussion of the ongoing randomized trials investigating the therapeutic potential of ranolazine in a variety of cardiovascular diseases.
authors.affiliation: Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
authors.forename: Christos G
authors.initials: CG
authors.lastname: Mihos
authors.affiliation: Columbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL, United States.
authors.forename: Rama K
authors.initials: RK
authors.lastname: Krishna
authors.affiliation: Columbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL, United States.
authors.forename: Nisharahmed
authors.initials: N
authors.lastname: Kherada
authors.affiliation: Columbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL, United States.
authors.forename: Maiteder
authors.initials: M
authors.lastname: Larrauri-Reyes
authors.affiliation: Columbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL, United States.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Tolentino
authors.affiliation: Columbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL, United States. Electronic address: osantana@msmc.com.
authors.forename: Orlando
authors.initials: O
authors.lastname: Santana
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D000069458:Ranolazine / Q000494:pharmacology / Q000627:therapeutic use*; D026941:Sodium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D026941:Sodium Channel Blockers; D000069458:Ranolazine
keywords: Cardiovascular effects; Non-anginal; Randomized trials; Ranolazine